**Core Concept**
The underlying pharmacological principle being tested involves the mechanism of action of **clofibrate**, a **fibrinic acid derivative**, used to manage **hyperlipidemia**. Clofibrate works by activating **peroxisome proliferator-activated receptor-alpha (PPAR-α)**, which regulates lipid metabolism. This activation influences the expression of genes involved in lipid synthesis and degradation.

**Why the Correct Answer is Right**
Clofibrate inhibits both cholesterol and triglyceride synthesis by activating **PPAR-α**, which leads to increased lipolysis and clearance of triglyceride-rich lipoproteins from the plasma. This results in decreased levels of **very-low-density lipoprotein (VLDL)** and consequently, reduced synthesis of **low-density lipoprotein (LDL)** cholesterol. The activation of **PPAR-α** also promotes the expression of **lipoprotein lipase**, an enzyme crucial for the hydrolysis of triglycerides.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because while **HMG-CoA reductase** is a key enzyme in cholesterol synthesis, clofibrate's primary action is not through its inhibition.
**Option B:** Incorrect as **ACAT** (acetyl-CoA acetyltransferase) is involved in cholesterol esterification, not the primary target of clofibrate.
**Option C:** Incorrect because **CYP7A1** (cholesterol 7-alpha-monooxygenase) is involved in bile acid synthesis from cholesterol, not directly related to clofibrate's mechanism.
**Option D:** Incorrect as it is not specified, but based on the context, the correct mechanism involves **PPAR-α** activation.

**Clinical Pearl / High-Yield Fact**
Remember, **fibrates** like clofibrate are particularly useful in treating **hypertriglyceridemia** and can also increase **HDL** (high-density lipoprotein) levels, making them beneficial for patients with specific lipid profiles.

**Correct Answer:** D. activating PPAR-α.